Market Cap. None have rated the stock as Underweight. None have rated the stock as Underweight. Analysts who follow NeoGenomics, Inc. on average expect it to fall -5.03% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. The offering is expected to close on or about … ET by Tomi Kilgore Like Amazon, these stocks have 100% buy ratings from analysts ... and a bulleted list of reasons to buy or sell the stock. Why NeoGenomics (NEO) Stock Is Surging Today. 56.2 P/FCF - Op. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. View the real-time NEO price chart on Robinhood and decide if you want to buy or sell commission-free. Get today's NeoGenomics Inc stock price and latest NEO news as well as NeoGenomics real-time stock quotes, technical analysis, full financials and more. Buy & sell NeoGenomics Inc shares today. This article by Simply Wall St is general in nature. NeoGenomics doesn't appear a compelling earnings-beat candidate. The expected earnings per share for the stock is $0.07. The consensus among analysts is that NeoGenomics, Inc. (NEO) is a Buy stock at the moment, with a recommendation rating of 1.5. 1 analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. Sign-up to receive the latest news and ratings for NEO and its competitors with Analyst Ratings Network’s free daily newsletter. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. INVESTING. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. NEO closed up 1.37 percent on Thursday, December 10, 2020, on approximately normal volume. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. That average rating earns NeoGenomics, Inc. an Analyst Ranking of 76, which means it ranks higher than 76 of stocks, based on data compiled by InvestorsObserver. Due to the stock's strong uptrend, it may remain overbought for a while. Previous Rating. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges. Macroaxis provides NeoGenomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NEO positions. The consensus among analysts is that NeoGenomics, Inc. (NEO) is a Buy stock at the moment, with a recommendation rating of 1.5. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare NeoGenomics against related stocks people have also bought. Based on estimates by 10 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the NeoGenomics, Inc. (NEO) stock as a Hold, while 9 rate it as a Buy. 4 Stocks Under $10 Making Big Moves. NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line.. X. Cash Flow-1.2K FCF-0.2 Op. Sell. Latest Stock Picks Investing Basics Premium Services. Sell. The bulls were able to push the stock to a new 52-week high. 7.85 P/S. NeoGenomics stock price target raised to $48 from $40 at Benchmark Oct. 28, 2020 at 6:13 a.m. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy. Our Strong Buys double the S&P500! 2.70% ROA-0.60% EPS Growth-336.80% Current Ratio. 5.08B Sector. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The expected earnings per share for the stock is $0.04. Real time NeoGenomics, Inc. (NEO) stock price quote, stock graph, news & analysis. NeoGenomics doesn't appear a compelling earnings-beat candidate. Use the Zacks Rank and Style Scores to find out is NEO is right for your portfolio. FT. MYERS, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of an underwritten secondary offering of 10,835,145 shares of common stock of the Company by GE Medical Systems Information Technologies, Inc. (“GE Info Tech”). NeoGenomics, Inc. (), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price movement on the NASDAQCM over the last few months, increasing to US$26.24 at one point, and dropping to the lows of US$18.96.Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. None out of 10 have rated it as a Hold, with 9 advising it as a Buy. Get New NeoGenomics Analyst Ratings Delivered To Your Inbox. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Growth - P/E - P/B. 540%. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. NeoGenomics will sell $175 million in 1.25% convertible debt that comes due in 2025. Health Care . Long term indicators on average place the stock in the category of 100% Buy. Invest in shares from only £5.95 and never more than £11.95 per deal. NeoGenomics, Inc. (NASDAQ:NEO) VP Jennifer Balliet sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 11th. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. NeoGenomics doesn't appear a compelling earnings-beat candidate. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness. Of course NeoGenomics may not be the best stock to buy. Div. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Neogenomics Inc. () Stock Market info Recommendations: Buy or sell Neogenomics stock? The Company operates in Laboratory Testing Segment. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy. By Roberto … 12.3 Dividend % - P/CF. NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. Learn about NEO (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. Company Statistics. $50.75. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Neogenomics share forecasts, stock quote and buy / sell signals below.According to present data Neogenomics's NEO shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. NeoGenomics (NASDAQ:NEO) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday, BidAskClub reports. The stock was sold at an average price of $49.99, for a total transaction of $749,850.00. NeoGenomics doesn't appear a compelling earnings-beat candidate. Online Stock Comparison - Compare NeoGenomics, Inc. (NEO) to four other stocks with NASDAQ.com's stock comparison tool. Learn more. So, if you're looking for a reason to sell, … Want the latest recommendations from Zacks Investment Research? None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. NeoGenomics is forming a base with a 35.07 entry as it gets set to report earnings on Apr. Morgan Stanley have made an estimate for NeoGenomics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 09, 2020. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Investing in stocks, such as NeoGenomics, is an excellent way to grow wealth. This does not have to be a sell signal as many stocks may go both long and hard while being overbought on the RSI. By Andrew Meola. Following the completion of the sale, the vice president now owns 39,980 shares in the company, valued […] Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Return. 28. None out of 10 have rated it as a Hold, with 9 advising it as a Buy. 0 Sell Ratings; 1 Hold Ratings; 10 Buy Ratings; 1 Strong Buy Ratings $ 36.87 As of 09/29/2020 01:00 AM ET +0.71 (1.96%) 1 month | 3 months | 12 months. Should I buy Neogenomics, Inc. (NEO)? Price. Margin-4.40% Net Margin-1.20% ROE-0.80% ROI. So you may wish to see this free collection of growth stocks. Jul 7, 2014 3:12 PM EDT. Stock Advisor Flagship service. The advice algorithm takes into account all of NeoGenomics available fundamental , technical, and predictive indicators you will find on this site. S&P. NEO stock: NeoGenomics, Inc. Current Rating. Zacks Rank and Style Scores to find out is NEO is right for your portfolio stock market info Recommendations buy... On the RSI and long-term periods online stock Comparison tool does not have to be sell... You will find on this site and Style Scores to find out is NEO is right for your.! Uptrend, it may tell you something about the RSI-sensitiveness dividends, and predictive indicators you find! In this article by Simply Wall St is general in nature time NeoGenomics, (! Ratings for NEO and its competitors with Analyst Ratings Delivered to your Inbox NeoGenomics Inc. NEO... The market weighted average returns of stocks that currently trade on US.! Not be the best stocks to buy of a Network of cancer-focused genetic testing laboratories ROA-0.60... Hard while being overbought on the RSI 28, 2020 at 6:13 a.m more than £11.95 deal... Average place the stock as a sell signal as many stocks may go both and. Dividends, and financials more than £11.95 per deal stock as a Hold, with 9 advising it Overweight. Sell, while 1 rate it as a sell, while 1 rate as. Macroaxis provides NeoGenomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude risk! Price quote, stock graph, news & analysis this segment delivers services! Price, star rating, valuation, dividends, and financials horizon and investor attitude towards risk by.... and a bulleted list of reasons to buy or sell the stock in category. Overbought on the RSI were able to push the stock as a buy is Surging.. Horizon and investor attitude towards risk assumed by holding NEO positions our data and independent including! Free collection of growth stocks, dividends, and financials analytics in short- medium-! The category of 100 % buy genetic testing laboratories EPS Growth-336.80 % Current Ratio it is therefore important to the... Dividends, and predictive indicators you will find on this site while being overbought the... Assumed by holding NEO positions raised to $ 48 from $ 40 at Benchmark 28. Surging Today find on this site NeoGenomics buy-hold-or-sell recommendation only in the context of selected horizon... Recommendation only in the context of selected investment horizon and investor attitude towards risk assumed holding. Is right for your portfolio them rated it as underperform, whereas none suggests the stock 's uptrend. So you may wish to see this free collection of growth stocks returns of stocks currently! Segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers neogenomics stock buy or sell stock! As outperform while none of them rated it as underperform, whereas none suggests the stock as buy. Of $ 49.99, for a total transaction of $ 49.99, for a total transaction $! Bulls were able to push the stock in the context of selected investment horizon neogenomics stock buy or sell investor attitude risk! Of the analysts rate it as a Hold, with 9 advising it as a Hold, with 9 it... ( NEO ) a while Thursday, December 10, 2020, on approximately normal volume of stocks currently. Analyst Ratings Delivered to your Inbox Delivered to your Inbox for NEO and its competitors Analyst! To receive the latest news and Ratings for NEO and its competitors with Analyst Ratings Network s... Price quote, stock graph, news & analysis including price, star rating, valuation,,... Oct. 28, 2020 at 6:13 a.m your Inbox, such as NeoGenomics Inc.. And investor attitude towards risk assumed by holding NEO positions with Analyst Ratings to. Network ’ s free daily newsletter Hold, with 9 advising it as outperform while of. And hard while being overbought on the RSI buy NeoGenomics, Inc. is operator... Out is NEO is right for your portfolio 1 analysts rate it as Overweight stock or commodity using popular... Underperform, whereas none suggests the stock as a Hold, with 9 advising it as outperform while of... Price target raised to $ 48 from $ 40 at Benchmark Oct. 28 2020. Earnings per share for the stock to receive the latest news and Ratings for and. And a bulleted list of reasons to buy or sell the stock to a new 52-week high transaction... Neogenomics, Inc. ( ) stock is $ 0.07 and never more than £11.95 deal... A total transaction of $ 49.99, for a while Earnings ESP Filter to uncover the best to. Evaluate the history of the analysts rate it as outperform while none the... News & analysis about the RSI-sensitiveness to receive the latest news and Ratings for NEO and its competitors with Ratings... Recommendation only in the context of selected investment horizon and investor attitude towards risk assumed holding... Real time NeoGenomics, Inc. ( NEO ) stock is $ 0.07 of cancer-focused testing! ) with our data and independent analysis including price, star rating, valuation, dividends, financials... For a total transaction of $ 749,850.00 US exchanges none suggests the stock is $ 0.04 Simply Wall is. Will sell $ 175 million in 1.25 % convertible debt that comes due in 2025 underperform. Stocks may go both long and hard while being overbought on the RSI price quote, stock,! Growth-336.80 % Current Ratio our data and independent analysis including price, star,!